论文部分内容阅读
目的就孟鲁司特治疗哮喘患儿的疗效观察进行探讨。方法选择2011年1月～2012年1月本院呼吸科收治的133例支气管哮喘患儿,随机将其分为对照组(65例)和治疗组(68例),对照组行常规治疗,采用酮替酚+支气管扩张剂(如茶碱、β2受体激动剂等)+布地奈德气雾剂;治疗组在其基础上加用孟鲁司特治疗。结果 68例治疗组患儿总显效率为86.76%;65例对照组患儿总显效率为55.38%。两组患者的临床疗效具有较大差异,具有明显的统计学意义(P<0.05)。结论孟鲁司特是唯一经FDA批准应用于6～12岁儿童的白三烯拮抗剂,适用于治疗各种程度哮喘,值得在临床上推广使用。
Objective To investigate the efficacy of montelukast in children with asthma. Methods From January 2011 to January 2012, 133 children with bronchial asthma admitted to the Department of Respiratory Department of our hospital were randomly divided into control group (65 cases) and treatment group (68 cases). The control group was treated routinely with Ketotubes + bronchodilators (such as theophylline, β2 agonists, etc.) + budesonide aerosol; treatment group based on the addition of montelukast treatment. Results The total effective rate of children in the treatment group was 86.76%. The total effective rate of the 65 children in the control group was 55.38%. The clinical efficacy of two groups of patients with great differences, with significant statistical significance (P <0.05). CONCLUSION Montelukast is the only leukotriene antagonist approved by the FDA for children aged 6-12 years and is suitable for the treatment of various degrees of asthma and is worth promoting in clinical practice.